Circadian Rhythm Sleep Treatment Market Forecasted to Cross US$ 1.23 Billion at a 4.7% CAGR by 2034

The circadian rhythm sleep treatment market growth in Japan is propelled by a heightened awareness of the importance of sleep health and its correlation with cardiovascular well-being. Addressing sleep disorders linked to heart health has become an essential component of preventive healthcare, with governmental initiatives and healthcare initiatives increasingly integrating such measures.

The global circadian rhythm sleep treatment market is estimated to be worth US$ 784.7 million in 2024, with projections suggesting growth to US$ 1.23 billion by 2034, reflecting a compound annual growth rate (CAGR) of 4.7% over the decade.

𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐚 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲 𝐨𝐟 𝐓𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭:
https://www.factmr.com/connectus/sample?flag=S&rep_id=9675

Sleep disorders have become increasingly prevalent in modern society, impacting millions of individuals worldwide. Among the various factors contributing to sleep disturbances, disruptions in circadian rhythm, the body's internal clock regulating sleep-wake cycles, play a significant role. However, emerging trends in circadian rhythm sleep treatment offer promising avenues for addressing these disorders and improving overall sleep quality.

Understanding Circadian Rhythm Sleep Disorders:

Circadian rhythm sleep disorders encompass a range of conditions characterized by disruptions in the body's natural sleep-wake cycle. These disorders can manifest in various forms, including insomnia, delayed sleep phase disorder, advanced sleep phase disorder, and irregular sleep-wake rhythm. Factors such as shift work, jet lag, and exposure to artificial light at night can contribute to circadian rhythm disruptions, leading to sleep disturbances and associated health consequences.

Emerging Trends in Circadian Rhythm Sleep Treatment:

Recent advancements in circadian rhythm sleep treatment focus on addressing the underlying causes of sleep disorders and restoring the body's natural sleep-wake cycle. Some key trends in this field include:

Light Therapy: Light therapy, also known as phototherapy, involves exposure to specific wavelengths of light to regulate circadian rhythms and improve sleep patterns. This treatment modality has shown promising results in managing conditions such as delayed sleep phase disorder and seasonal affective disorder (SAD). Light therapy devices simulate natural sunlight and can be used in conjunction with other interventions to reset the body's internal clock.
Chronotherapy: Chronotherapy involves gradually shifting bedtime and wake time to align with the desired sleep-wake schedule. This approach aims to reset the circadian rhythm and promote healthier sleep patterns over time. Chronotherapy may be particularly effective for individuals with delayed sleep phase disorder or irregular sleep-wake rhythm.
Melatonin Supplements: Melatonin is a hormone produced by the pineal gland in the brain, which helps regulate sleep-wake cycles. Supplemental melatonin is commonly used to treat circadian rhythm sleep disorders, particularly jet lag and shift work-related sleep disturbances. Emerging research suggests that timed administration of melatonin supplements may improve sleep quality and duration, especially when combined with other behavioral interventions.

𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬:

Vanda Pharmaceuticals, Inc.
Akeda Pharmaceutical Company
LimitedIdorsia Pharmaceuticals Ltd.
VU University Medical
CenterNeuraxpharm
The Sunbox Company

𝐑𝐞𝐚𝐝 𝐌𝐨𝐫𝐞:https://www.factmr.com/report/circadian-rhythm-sleep-treatment-market

𝐂𝐨𝐦𝐩𝐞𝐭𝐢𝐭𝐢𝐯𝐞 𝐋𝐚𝐧𝐝𝐬𝐜𝐚𝐩𝐞:

In an effort to cater to a broader clientele, industry frontrunners are introducing novel and innovative products into the market. Multinational corporations are also expanding their presence into emerging markets in developing nations to bolster their consumer base and fortify their market standing.

In December 2019, Japanese pharmaceutical company Eisai Co. announced that the United States Food and Drug Administration had granted approval for Dayvigo, a medication designed for adult patients afflicted with insomnia. The FDA's decision was based on two late-stage trials, which compared Dayvigo to a placebo over durations of up to one month and six months in patients suffering from insomnia, with approved dosages of 5 mg and 10 mg.

𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧 𝐨𝐟 𝐂𝐢𝐫𝐜𝐚𝐝𝐢𝐚𝐧 𝐑𝐡𝐲𝐭𝐡𝐦 𝐒𝐥𝐞𝐞𝐩 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡

By Treatment :
Devices
Medications
Chronotherapy

By Disorder :
Delayed Sleep Phase Syndrome
Advanced Sleep Phase Syndrome
Non-24-hour Sleep-wake Syndrome
Irregular Sleep-wake Disorders
Shift Work Disorders
Jet Lag

By Sales Channel :
Institutional Sales
Retail Sales

By Region :
North America
Latin America
Europe
East Asia
South Asia & Oceania
Middle East & Africa

Emerging trends in circadian rhythm sleep treatment offer hope for individuals struggling with sleep disorders by providing innovative and effective solutions to restore healthy sleep patterns. By addressing the underlying causes of circadian rhythm disruptions and leveraging evidence-based interventions, healthcare providers can help individuals achieve better sleep quality and overall well-being. As research in this field continues to advance, the future of circadian rhythm sleep treatment holds great promise for transforming the landscape of sleep medicine.

𝐓𝐨𝐩 𝐑𝐞𝐥𝐚𝐭𝐞𝐝 𝐑𝐞𝐩𝐨𝐫𝐭 𝐢𝐧 𝐭𝐡𝐞 𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲

Sleeping Aids Market
https://www.factmr.com/report/sleeping-aids-market
Insomnia Treatment Market
https://www.factmr.com/report/insomnia-treatment-market
Actigraphy Sensors & PSG Devices Market
https://www.factmr.com/report/2829/actigraphy-sensors-psg-devices-market

𝐂𝐨𝐧𝐭𝐚𝐜𝐭:

US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583, +353-1-4434-232
Email: sales@factmr.com

𝐀𝐛𝐨𝐮𝐭 𝐅𝐚𝐜𝐭.𝐌𝐑

We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client's satisfaction.

This release was published on openPR.